Potentials of ribosomopathy gene as pharmaceutical targets for cancer treatment

Mengxin Wang; Stephen Vulcano; Changlu Xu; Renjian Xie; Weijie Peng; Jie Wang; Qiaojun Liu; Lee Jia; Zhi Li; Yumei Li

doi:10.1016/j.jpha.2023.10.001

Potentials of ribosomopathy gene as pharmaceutical targets for cancer treatment

J Pharm Anal. 2024 Mar;14(3):308-320. doi: 10.1016/j.jpha.2023.10.001. Epub 2023 Oct 13.

Authors

Mengxin Wang^{1

2}, Stephen Vulcano³, Changlu Xu⁴, Renjian Xie^{1

5}, Weijie Peng¹, Jie Wang⁶, Qiaojun Liu^{1

7}, Lee Jia⁸, Zhi Li⁴, Yumei Li^{1

7}

Affiliations

¹ Key Laboratory of Biomaterials and Biofabrication in Tissue Engineering of Jiangxi Province, Gannan Medical University, Ganzhou, Jiangxi, 341000, China.
² School of Rehabilitation Medicine, Gannan Medical University, Ganzhou, Jiangxi, 341000, China.
³ Autoimmunity and Inflammation Program, HSS Research Institute, Hospital for Special Surgery New York, New York, NY, 10021, USA.
⁴ Division of Oral and Systemic Health Sciences, School of Dentistry, University of California, Los Angeles, CA, 90095, USA.
⁵ School of Medical Information Engineering, Gannan Medical University, Ganzhou, Jiangxi, 341000, China.
⁶ Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, Institute for Liver Diseases of Anhui Medical University, School of Pharmacy, Anhui Medical University, Hefei, 230032, China.
⁷ School of Basic Medicine, Gannan Medical University, Ganzhou, Jiangxi, 341000, China.
⁸ Institute of Oceanography, Minjiang University, Fuzhou, 350108, China.

Abstract

Ribosomopathies encompass a spectrum of disorders arising from impaired ribosome biogenesis and reduced functionality. Mutation or dysexpression of the genes that disturb any finely regulated steps of ribosome biogenesis can result in different types of ribosomopathies in clinic, collectively known as ribosomopathy genes. Emerging data suggest that ribosomopathy patients exhibit a significantly heightened susceptibility to cancer. Abnormal ribosome biogenesis and dysregulation of some ribosomopathy genes have also been found to be intimately associated with cancer development. The correlation between ribosome biogenesis or ribosomopathy and the development of malignancies has been well established. This work aims to review the recent advances in the research of ribosomopathy genes among human cancers and meanwhile, to excavate the potential role of these genes, which have not or rarely been reported in cancer, in the disease development across cancers. We plan to establish a theoretical framework between the ribosomopathy gene and cancer development, to further facilitate the potential of these genes as diagnostic biomarker as well as pharmaceutical targets for cancer treatment.

Keywords: Cancer treatment target; Pharmaceutical target; Ribosome biogenesis; Ribosomopathy gene.

Publication types

Review